Results 261 to 270 of about 21,604,258 (289)
Some of the next articles are maybe not open access.

Cancer gene therapy with T cell receptors and chimeric antigen receptors

Current Opinion in Pharmacology, 2015
Viral and non-viral gene transfer technologies have been used to efficiently generate therapeutic T cells with desired cancer-specificity. Chimeric antigen receptors (CARs) redirect T cell specificity toward antibody-recognized antigens expressed on the surface of cancer cells, while T cell receptors (TCRs) extend the range of targets to include ...
Hans J, Stauss   +2 more
openaire   +2 more sources

The Cardiovascular Complications of Chimeric Antigen Receptor T Cell Therapy

Current Hematologic Malignancy Reports, 2020
Chimeric antigen receptor T cell therapy is gaining clinical use in the management of B cell lymphomas. As the use of this unique treatment option increases, its associated toxicities will require recognition and treatment. In this review, we aim to discuss the cardiovascular toxicities of chimeric antigen receptor T cell therapy and our approach to ...
Faizi A, Jamal, Samer K, Khaled
openaire   +2 more sources

The pharmacist’s role in chimeric antigen receptor T cell therapy

Journal of Oncology Pharmacy Practice, 2020
The emergence and efficacy of chimeric antigen receptor (CAR) T cell therapy in previously incurable malignancies represents a promising paradigm shift in cancer care. However, it is not without significant clinical, operational, and financial considerations.
Jennifer P Booth   +2 more
openaire   +2 more sources

Chimeric antigen receptor T cell therapy: 25years in the making

Blood Reviews, 2016
Chimeric antigen receptor (CAR) T cell therapy of cancer is generating enormous enthusiasm. Twenty-five years after the concept was first proposed, major advances in molecular biology, virology, and good manufacturing practices (GMP)-grade cell production have transformed antibody-T cell chimeras from a scientific curiosity to a fact of life for ...
Saar, Gill   +2 more
openaire   +2 more sources

In vivo chimeric antigen receptor (CAR)-T cell therapy

Nature Reviews Drug Discovery
Chimeric antigen receptor (CAR)-T cell therapy has transformed the outcomes of patients with haematological malignancies, yet its use is limited by labour-intensive manufacturing, constrained production capacity and variable clinical performance. In vivo CAR-T cell engineering, in which CAR-T cells are generated directly inside the patient's body ...
Adrian Bot   +14 more
openaire   +2 more sources

Critical Care Management of Chimeric Antigen Receptor T-Cell Therapy Recipients

Ca-A Cancer Journal for Clinicians, 2022
Sandrine Valadè   +2 more
exaly  

Side-Effect Management of Chimeric Antigen Receptor (CAR) T-Cell Therapy

Annals of Oncology, 2021
Carsten Müller-Tidow   +2 more
exaly  

Chimeric Antigen Receptor (CAR) T-Cell Therapy

JAMA Oncology, 2017
John M, Pagel, Howard Jack, West
openaire   +2 more sources

Home - About - Disclaimer - Privacy